<SEC-DOCUMENT>0001193125-13-249338.txt : 20130606
<SEC-HEADER>0001193125-13-249338.hdr.sgml : 20130606
<ACCEPTANCE-DATETIME>20130606090042
ACCESSION NUMBER:		0001193125-13-249338
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130606
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130606
DATE AS OF CHANGE:		20130606

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		13896094

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 200
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d548334d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>of the Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): June&nbsp;6, 2013 (June 6, 2013) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ARCA biopharma, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-22873</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36-3855489</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8001 Arista Place, Suite 430, Broomfield, CO 80021 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(720) 940-2200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s telephone number, including area code)
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Former Name or Former Address, if Changed Since Last Report) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;8 &#151; Other Events </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01. Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;6, 2013, ARCA biopharma, Inc. announced that
the paper &#147;Prevention of Atrial Fibrillation by Bucindolol Is Dependent on the Beta-1 389 Arg/Gly Adrenergic Receptor Polymorphism&#148; was published in the journal <I>JACC: Heart Failure
</I>(<U>http://heartfailure.onlinejacc.org/article.aspx?articleid=1691088</U>), a publication of the American College of Cardiology. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;Gencaro&#153; Potential Efficacy in Preventing Atrial Fibrillation Paper Published in JACC: Heart Failure&#148; dated June 6, 2013.</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: June&nbsp;6, 2013 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARCA biopharma, Inc.</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Christopher D. Ozeroff</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Christopher D. Ozeroff</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">SVP and General Counsel</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEX TO EXHIBITS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release titled &#147;Gencaro&#153; Potential Efficacy in Preventing Atrial Fibrillation Paper Published in JACC: Heart Failure&#148; dated June 6, 2013.</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d548334dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right">


<IMG SRC="g548334ex99_1logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Christopher D. Ozeroff </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and General Counsel </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">720.940.2100 </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px;padding-bottom:0px; " ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GENCARO<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> POTENTIAL EFFICACY IN PREVENTING ATRIAL FIBRILLATION PAPER PUBLISHED IN JACC: HEART FAILURE </FONT></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Pharmacogenetic Enhancement of Effectiveness for Prevention of Atrial </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fibrillation in Patients with Heart Failure and Reduced Left Ventricular Ejection Fraction </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Broomfield, CO, June&nbsp;6, 2013 </I>&#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted
therapies for cardiovascular diseases, today announced that the paper &#147;Prevention of Atrial Fibrillation by Bucindolol is Dependent on the Beta-1 389 Arg/Gly Adrenergic Receptor Polymorphism&#148; was published in the journal <I>JACC: Heart
Failure</I> [http://heartfailure.onlinejacc.org/article.aspx?articleid=1691088], a publication of the American College of Cardiology. The lead author on the paper is cardiologist-electrophysiologist Ryan G. Aleong of the University of Colorado,
Anschutz Medical Campus and the senior author on the paper is Dr.&nbsp;Michael Bristow, the Company&#146;s Chief Executive Officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">The authors investigated the potential efficacy of the developmental drug
Gencaro<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> (bucindolol hydrochloride) in reducing the incidence of new onset atrial fibrillation (&#147;AF&#148;)
in patients with advanced heart failure with reduced left ventricular ejection fraction (&#147;HFREF&#148;), and the potential impact of certain cardiac adrenergic receptor (&#147;AR&#148;) genotypes on this efficacy. The study was based on a
post-hoc analysis of the Phase 3 clinical trial of 2,708 HFREF patients known as the Beta-Blocker Evaluation of Survival Trial (the &#147;BEST Trial&#148;), including a DNA substudy of 1,040 patients in the Trial. The study analyzed Gencaro&#146;s
potential efficacy in reducing the risk of developing new onset AF in the 2,392 patients who entered the Trial not in AF, including the 925 patients in the DNA substudy who entered the Trial not in AF. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The study found that in the overall study population, patients who had received Gencaro had a 41% lower risk of new onset AF (p = 0.0004) compared to
patients who received a placebo (this compared with a 43% lower risk of new onset AF (p = 0.014) from Gencaro treatment compared to placebo in all genotypes in the DNA substudy). However, the risk of new onset AF was reduced by 74% (p = 0.0003)
compared to placebo in those patients in the DNA substudy who received Gencaro and who possessed the beta-1 AR position 389 arginine homozygous (&#147;beta-1 389 arginine homozygous&#148;) genotype. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company estimates that the beta-1 389 arginine homozygous genotype is present in about 50% of the general U.S. population, and was present in about
47% of the patients in the BEST DNA substudy. The BEST Trial was sponsored by the National Heart, Lung and Blood Institute of the National Institutes of Health, and the Cooperative Studies Program of the Department of Veterans Affairs. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The authors propose that the greater reduction in AF seen by patients with the beta-1 389 arginine
homozygous genotype who received Gencaro may be due to the interaction of Gencaro&#146;s pharmacology with the pathophysiology of AF, where, according to other research, both acute and chronic beta-1 AR stimulation may be important contributors. The
paper notes that the currently approved anti-arrhythmic drugs are subject to multiple adverse effects in HFREF patients, and have not been associated with improved cardiovascular outcomes in those patients. The paper also notes that approved
beta-blockers exhibit only modest efficacy for reducing new onset AF in HFREF patients, and none are currently approved for this indication. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jonathan Piccini, MD, Director of the Cardiac Electrophysiology Clinical Trials Program at Duke University Medical Center, said &#147;AF is a common
arrhythmia that is best avoided, particularly in left ventricular (&#147;LV&#148;) dysfunction-heart failure patients where it can worsen the clinical syndrome and/or appear to reduce the efficacy of some of the most effective heart failure
treatments, such as conventional beta-blockers. Although catheter ablation may be effective for treating/preventing AF episodes, medical therapy still needs to be tried first and is used on AF recurrence. The current problem with drug therapy for
preventing AF in an LV dysfunction-heart failure patient is that the FDA-approved anti-arrhythmic agents have adverse safety profiles, due to pro-arrhythmia and/or myocardial depression. Based on the data of Aleong et al, Gencaro may potentially not
have these adverse effects. In addition, compared to standard anti-arrhythmic agents or conventional beta-blockers, Gencaro has the potential for higher efficacy in preventing AF in patients with the beta-1 389 arginine homozygous genotype.&#148;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stuart Connolly, MD, Director of the Division of Cardiology at McMaster University in Hamilton, Ontario commented, &#147;The paper by Aleong
et al suggests that pharmacogenetically targeted Gencaro may have a major effect (&gt;70% reduction in event rate) on prevention of AF in an advanced LV-dysfunction heart failure population with the beta-1 389 arginine homozygous genotype. In
addition, in this same population and genotype from the BEST Trial, the authors have previously published results indicating potentially substantial beneficial effects on heart failure endpoints and potential prevention of ventricular tachycardia or
ventricular fibrillation, suggesting that Gencaro may not be accompanied by the same sort of safety issues that plague ion channel blocking anti-arrhythmic agents. Therefore, in the estimated approximately 50% of LV dysfunction-heart failure
patients who have the beta-1 389 arginine homozygous genotype, Gencaro has the potential to be a promising treatment for preventing AF in at-risk patients.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Michael Bristow, MD, PhD, cardiologist/clinical pharmacologist, also commented, &#147;We believe the 74% reduction in risk of new onset AF in the beta-1 389 arginine homozygous genotype suggests that
Gencaro warrants further study in HFREF patients at risk for AF. Previous studies of the BEST Trial data have suggested that Gencaro may provide multiple benefits for such patients, including AF prevention, rate control for patients with persistent
AF, and improved outcomes for both those patients that are able to maintain sinus rhythm and those that do not. We plan to assess Gencaro&#146;s potential efficacy in the Phase 2b/3 GENETIC-AF clinical trial, which we plan to conduct in beta-1 389
arginine homozygous HFREF patients, post electrical cardioversion for persistent AF.&#148; </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCA plans to evaluate Gencaro&#146;s efficacy in preventing AF in patients with the beta-1 389 arginine
genotype in a 620 patient, Phase 2b/3 clinical trial, known as GENETIC-AF, in which Gencaro will be compared to the beta-blocker metoprolol CR/XL. ARCA has created an adaptive design for GENETIC-AF, in which the trial is planned to be initiated as a
Phase 2b study in approximately 200 HFREF patients with the beta-1 389 arginine genotype. Depending on the results of the Phase 2B portion, the trial could then be expanded to a Phase 3 study by enrolling an estimated additional 420 patients. ARCA
and Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases including cardiac rhythm disorders, have agreed to collaborate on the Phase 2b portion of GENETIC-AF trial that will include continuous monitoring of
the cardiac rhythms in all 200 patients enrolled in this Phase. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AF is considered an epidemic cardiovascular disease with an estimated
prevalence of at least 2.7&nbsp;million Americans in 2010. The approved therapies for the treatment or prevention of AF have certain disadvantages in HFREF patients, such as toxic or cardiovascular adverse effects, and most of the approved drugs for
AF are contra indicated or have warnings in their prescribing information for such patients. ARCA believes there is an unmet medical need for new AF treatments that have fewer side effects than currently available therapies and are more effective,
particularly in HFREF patients. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About ARCA biopharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">TM</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (bucindolol hydrochloride), is an investigational, pharmacologically
unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first
genetically-targeted atrial fibrillation prevention treatment. For more information please visit <U>www.arcabiopharma.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Safe Harbor
Statement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release and the associated presentation may contain &#147;forward-looking statements&#148; for purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the ability of genetic variations to predict individual patient response to Gencaro, Gencaro&#146;s
potential to treat atrial fibrillation, Gencaro&#146;s potential to treat ventricular tachycardia or ventricular fibrillation, and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such
statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including,
without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and operational requirements; results of earlier clinical
trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive
products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended
December&nbsp;31, 2012, the Company&#146;s Registration Statement on Form S-1 (Registration No.&nbsp;333-187508), and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g548334ex99_1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g548334ex99_1logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`3@#=`P$1``(1`0,1`?_$`+@```("`P$!`0``````
M```````)!P@#!@H"!00!`0`!!`(#```````````````(!`8'"0,%`0(*$```
M!@$$`0,"`@8&"`<````!`@,$!08'`!$2""$3%`DQ(D$546%Q,B,6@4)28B0*
MD:%RTD-3DQC",S1$9"47$0`!`P($`P0&!0D)`0`````!``(#$00A$@4&,1,'
M05%A"'&!D2(R%-%2TG,5\*&Q0F*24V,DP>'Q<D.3LS0V"?_:``P#`0`"$0,1
M`#\`[7L^9K=4`&E?K9T`L+Y+W*[I0A%PCFO,Q2"5)0#HF<*&)^Z<HAQ-OMK7
M#YY_.+JO0N.VV%TY?".H%[$)I)W-;(+2',0"&/#F&5Y;\,C7`,<'4X%94Z=[
M%AW$7ZEJ@=^&QG*&@D9W4[Q0T'>",115B99]S*[,7C:2@0VX`8(6"W';??;_
M`.O_`$AK7YLKS=^=+>5PUMIN?+:U%7G3=-Q[Z?TE3^A92N>G^QK8>]:>]W<V
M7[:VUMF'+I@W4M7(1\[##08!^CP)8\-_.I9;<ZO>:":%IU+<SY7D''Y"P;4=
M_NVH''#^]6_/M'9K20RTH/O)?MK]JN6\N)CP&R\%!`A@#\HA1'8X`<H@`L-A
MY%$/].KHO>J7F3AC+!N![92!3^BL216A!H;?&H5-'M79[L?EJM^\D^VM;?YK
MS,U,?A:?W?'$T)!_:8`W$H[1WZ`U'[?G7SSD:`)+C1]U<QC22&'3]-K0=G_4
MK[5W5ILK8\U`^TX_S9?MK]M'[,WAA8FA+D^3FH5PHFU=H@RCV2[,%CE*5VB=
MJ@VY"D80Y`<1+PW\;[:LGH[_`/1+KCMKJ#;6O6.\;J^U)Y6P3QFVM;:2WSN#
M><QT$4-<AH7AY+<F8@%V5>-=Z6[?N=->[0XS!?-!<TYWN#J?JD.+N/93&M.R
MJ8:U=(/6K=XU5*LU=H).6ZQ!W(J@NF55)0H_B4Z9@$/U#K?AIFI6.LZ;;ZQI
M<C9M-NH&312-^%\<C0]CV^#FD$>!4;9HI+>5T$P+96.+7`\00:$>HK/JN7&C
M1%63M?V/B>L>+QO;UHWE))]-QT!!Q"RPI@\>O"N7*IU2IJ$7!L@R8JB)P$``
M_$!'SY(IKQ_=(G(U)JUZ@E"J1-K@HV=9"4Y3B1"2:).R)*"01`JJ15=C!]0$
M-AT1;AHBC[)UVE,?5)W9HBC6/(;IHLB0U<JIXPLPJ@H54RCI$)5XQ;*$0$@`
M)0.)Q$P;`/G8B7I._*CCJFSB]>OV&,PT64;D,86UD80K-10`'8ID$_S(QUT5
M/ZJA`%,?P-HBV6D?(TTR6DN\Q_UISO:XM%15,)B,CZ]^4K'1X^J1&07ETFJB
MQ`,&Z8'$X;AN'G1%^II\EF*(JR(5K*]!R?A5RY6])!S?H`R3=8@&`IW*'Y6+
MY5RV2$0Y'3*8H;Z(F!5RRP%OA(^QUB783D'*MR.H^4C7*;IFZ04`#%4262,8
MH^!\A]0_'1%]O1%"F9>PV(L"0QI?)ERC($QTC*,8D5#.YN1-L8$BM(IF1=\9
M-50O$%1("11WW,&PZ(JA0?>7)V7A74Z]=9KO;XQ(%@0L5J<Q5:@9,"%W(O'/
MI"7C45T.7@P`<3;A^G1%EM/:;MMC9J[F+_U/<+5]MQ-[ZE3C"R.13(4%'2AV
M$?//WJ9$TQV*)DP#D`B/CSHB^IUK^1*@=C<BL<71M&ME8LKN/E7PKS"\*:/W
MB&CAX[0(DWD%I#U2)MQ`0%/[3?7;1$P_1$:(JJ=L^TE=ZM4N"L\PT))O;!8V
M$.PC1.8#*-"KHKSCL"I&*IR8PX+*D_`RA`+YWVT160K4\QM-=@[+&*%5CYZ)
MCY=F<A@.`MY!JDZ3`1*(AR(578P?4#`(#YT1?;T1&B)5?8(RKG-EL;F,)DTE
M(@I-S"/I)C!1JI@*7?P`G,([!^([Z^<;SBZ#=[J\YFYM..>2WCEL<*DAK?PZ
MT<6CN!-20*8DE2SZ>%D&Q+.44#B)/6>:\+#5HANZ.BW,J5N"FQ453;@D"@CN
M`*B.YBE4-XW#8"B.XB`;ZDST?Z;:?!!%:Y!#4`!U*`&E0'5&`[*^LFE2J36=
M1DCS2#WJ<1VT\/R\.*L!$4)PK&RK)RV%M(QY491%142D3=-3^DW]-)P<01,F
M(*^H`@;8=M34T+ILYNF7-E/$([RW#96UH`]AHW!Q]W*<V?`T6.;S7V"YBFC=
MF@D)8:8T.)J0,:X4X+;'U&:+R!I#FV58LH)BZ6!NJFKN[3CV[1-$A43&$3D>
MF*8P?CL.KTO=@V%Q>F]:(WVD5G&YV5P=5XB:P-%"3\9!/H*ZJ#6YF0<@YFS/
MF<!4$>Z7%U37O;4!099ZTZ8H%=2!1;K/-U46NW%8Q#")A<*)[;HIF-^Z4W$3
M`("`<=1OWYT]=!9NNM0C#)YLQ:PMHX@U]X@"K03PK0FH(]U7QI6JQS2<J`YF
M,P)[!X`]I[_I5?K&V!N85BCN;[^1?`[CR'S]OD1_4'TUJQZ_].6V1=J]C'ED
M:3GI3$=Y_*JRCH]T91RW<$TO"#I=WBZHJN%#*G",21*8P[B"2(`DD0!_LD3*
M`!^H-;X/)_?WFH^7+:TU[(Z25FFQQ@GB&1M#&-]#6@`>`45]]Q,AW7>-C%&\
MTGUG$GUE2OJ2RM%&B+G=^3JT6K.&0KK`TG_&4+JW5/S>^2#7FNS-/SSV+:GC
MUP*)BDF(I7U$@*(!L7U/T;Z(K:?$3FU&^X0FL:OGQ5YO&4N0B!%1$JYX*;%T
MK'II%$"D.A'ILP)]N_'F`#^&B)MVB(T1<\'S2+-V5_PTL!$DEW,!:2JK$13]
M98B"\$"15E0+ZARI>J;B!A$"\AV^HZ(FE?'BW:(]0,,*M$$4??5=F_<F13(F
M+AVX02%=RMP`.:ZO$.1A\CMHBB'Y5L>P%FZQR]N<LVA+#1Y1C)QDN*!1>IL1
M!<\C&D6`@G%![Z)!$H^`$OC;<=R*JGPR98L$TCE3%TA(N7U>KJ%?G:\V65%0
ML6O)J2R,DBB"@B9)JJ1BCP3)]A!*.P!OY(FI=INP]<ZR8@G\E3OI.7B!!CJU
M$G,;E+V-XBL$6S$B9BK>U.Y*4%3AL"91\F#<!T1(EZ<8HMO?[/-AS!F^2D9^
ME560;/Y=!8XH,I5\LLJJQJD<1$$DF,:@D@`.B-O2.4BH"`@8V^B+I4AX:)K\
M:TAX.-8Q$4Q2*@SCXYJBS9MDBAL!$FZ!$TB!^G8/(^1\Z(OH'(50IB'*4Y#E
M$AR'`#%.4P"!BF*("!BF`=A`?`AHB6#=>K:F,>Z^',^XCJJB<':5['"Y'CX=
MN0L=!N'\6+(U@,W$`3:-Y-!X5(2(@!"G1,82@(B82)H&B(T1<U/R46^U9YR%
MDB9JP"YQ5UB9UZLSC]OLZCI"SV>49(*KLSI"I_C6@65-!<!V`J:(^-PWT1,A
M^*W."64^M[&JOG_NK%C"3?5IWZZA1>.HY=0LTP>B3?D+9)*7*V*;;;^%MHB9
MKHB-$2H\\'$<[W<O$3;.(+;COR$HUZ(W(4`_M#_3K1=URL(9O.)N^X`_J#/8
MM'KTVS]O&E/9BI6[(--@6&.&67_FD4FXTC7+\4D'M2D99H<P$!TU:.DW#-,W
MG9%0H)LS;;[B*H&'_5J:G231KB[MXH+O3)[BU%!S&LD:]@\"*,./UP33!67N
M6Y9"7/ANHXI1CE+FD.](^+]VB^G;+@L[N):HU>/4H>NI(-$DW!_2>JJ+IIKK
M$?*I`F94&RJHID)OP`I0\;^=5FI;[FW!ON7;%K+-'H.F986M<<LCGT#G\PMH
M7!KBYK1\.4#"HJN#3M'CM]'_`!25C#>7!+B0*M`!(&4&M*@5)XU)Q4Z0["/;
M0I7Z3T".40(<I#'$2J"`E.'JD-N10HF#;80'4C=,L[*WTL7<4@$K0",<#VXC
M@1X%6-=3327?)>PECJC_``[5J]R:)2<:6>:5Z4L+N125,L]$BRC!D=JH9J9-
M!)AZ9R@F=/[0,`EV#5G[SL(=2T_\8AL;B^N9FNJ\YG1L+"6$-$1!%",`["G8
MNSTB5]M<?)23QV\<9%&X!S@1FJ2ZHQ!QIBJ2747*1U/=('04,*Q`(HAZ`E`O
M(!`""0@_;QV$?KO]=:R>OFF<RRN?FX7,>Z-W%I;B,.%`.&%*>/'%9RV\8W`<
MIP<T4X&J93@(>6)ZB/\`\#_Q#K9GY0(Q#Y>MNQ#@VUI['%1TZ@?^MO/O/[%,
M6I+JS%%&<LI0.%L2WS)UD=D9152KSV146,(<A7$H-V9$R;"90YW:Q`X@`CMO
MHB7QT'P<O=>J60;GE&-%S;>V$A.7NU>N!N#^.F'#Z1JRR95#;)IF0D`4`"[%
M^GC1$GGH+D:7ZH][U\4W)][%O(SM@Q#:O='%-@C(-7Q5$)4WT*/!Q#BFFIY#
M98?P'1%UR:(C1%S7?.@_*SR#@PHJ<1/7[B.VP?@XK>WU#]>B)AWQ^]C<!U[I
M_AJ*LN:L65Z;AJDS:R\+/7ZK0\TP=-T$P61<13^4;ORG+]`_A^1\!OHBK)\A
MO:V$[*4]IUBZI(S&9;=/3\:\M\G2(N2DH2`BVRATV[1[-%:_E/H3`JJ\E@5%
M)($-S&*`@(D5P?CFZ7O>I^.I1_=%V[K*-^%@YM!&JB2[2&91Y7!XR$062YIG
M7:*/U_643.8BG(OD>.B);WSE9.=$M.&\:)/1191T;-VAZT3/M[I2549M6:CE
M,=P,#<T2?TQV\")M$3$/B7J3"N=,Z1+-!247O$I+7!\J4@@K[AZDP8"BHH8`
M$X)EC`$``>(<AV\[Z(F7:(C1$:(C1%7WM-FF+Z^X#R7E23=)M#UVM2!8914Q
M"D/9)!!1C7$!`_@P+3*Z)1#ZB`CHBI;U-ZNJRO1.VURY,!3O/8V*MU\L99$Q
M55&MGLJ3HM8<BLJ)]D6B;5BY3`1$A!\[!YT1**^+?,#K`W<:3Q':'J[*.N#B
M?QW)E>E%)-&<KSJ0-&./1,0IB+2;^/12(8`^XJA?P$-$763HB-$2?NPTF+7L
M!?T>0@)G,`)=A`#`):U#'$2#^'@-:'_,#J\-CYP]W02&AYMBX>G\.LP/8>"E
MYL&VYO3S3W_LR_\`-(M^QK9&+3T'$K991J@D8JGY;&NG?N76QM]O5*)V:0[_
M`%`^PB4-2[Z1;FLX[>*YU+49XXQ0\F-[\[\II\0K&VI&(=0JT]RZ?-(71VUO
M&YYJ,[P*#U?$?4O65*W9(BU$NT%#2;F!L+-N]!DGL^F8DR*2:`K2K9OZC@C=
M_P"CZQ%A("?%0H;[ZL'JIMK>'3KJ+)OO0K*\N=DZR&396-=//:/#&L=SV1AS
MVQS.:96REHC`>UF;,0%4;9U#3-0TC\%O9HF:C;.+<Q]V.0$DT830$MKE+:UJ
M":462LW"VV$B47%1TDH*A@26<*MUTF+,3'!(RKQVJ4J#=)$P[")S%#?Q]1#6
M0MH=3]?W6UFF:):W,DCB&EQ8\1LJ:%TCR`QC0>.<C'#B0%2ZGHFFZ<3<W<D8
M`Q`!!<[MHUHQ)/@#ABI=NLE'0<2QK#F7FH&6C&115<`NLM#RBCL@.U'#<D<`
MJ*)JK+#P-R$NP^=9IW?J%AHNC1:%=W=S9:E;PU<[,70RN>,[BWE8D9C[IK2G
M%6EH]O/>W3]1BBAFMI'X"@#V!ON@'-A@!B.*HY=IM0RJP&<BZ,'J?Q#+'4`W
MU$!*8QC"`C]1#][?P/G?6LGKGN=@M;ELLSGG*:.KF\:@&OQ>BN*SIMZQ#0TA
MN4=U*)J_78XJX>IB@CN)XX#;_P"T81^GX?76U;R?R<[R\;<EX9K2OM<2HP=1
M6Y=XWK>Z139J3"LE(Y^6.^3V5KYUZZ(X[D?;6C,ML";L[IL<A_R^$B&+ST8Z
M72/R(FT?%>`Z+R`-Q;E\^=A(I6@^A?;2LPL378#O3<XN#@8YG$P\:VJ].*W8
M1L>@1LR:(E&H&$$T$$RE#<1'8/KHB0Q\EG7C*/4C-E,O-OR#(Y'?Y`%6T(7I
M5@SBW2TY7GT>K((/1C&$<Q3=+K/MR?PRG4+R$>7G1%UE]3<X1O8OKWC#++%Z
M@\>66JQ"UC(APVC[26.:GGXM0$BE2!9B_5,0P%^W?Z:(K&:(N6[_`#`4F##)
M'7X!4`OJ5N[^-P`?M<UC_5YT16]ZL=#.O'9KX],6*3U(B8Z_VW';5TVR(P!=
M.>CYY9F44)43`L9HY.10VXD5243'^SHB2YUHSCD#XT.Y;^KY+CS,XR/E_P"3
M,GPX)I*I.X%9R!4;%#.$^7N19$%0S91)0R"@F/N!MO!%VO5VP0UK@HFRUZ29
MR\'.,&TG%2<>X2=LGS)VD55!PV<H&.BLD<AO!BB(:(N9[Y_JF_AK7@S))4-X
MV<C;'5W#M,IMV[B$/'/$$W9_)2%7_.1]+?;<0-MOHB9+\-F2H?('2*D1T>Y;
MG>X_F)>E2S<A_P#$).F*,?(@LJD8>8)K$E``IP#@82B`>0'1$U71$:(L:JJ2
M"2BRZB:**1#**JJG*FFF0@"8QSG,(%(0H!N(B.P:(O93%.4IBF`Q3`!BF*("
M4Q1#<#%$-P$!`?`Z(D2?)_-SW9+L/UYZ$8]F?9OK(Y-D/(+QIQ=I1\&P.\."
M4HV,59#U8AO#_F!$SD$3<B[@(#L)%.['HWW`BV;*/CN^%V:,8UJV8L&R57II
M4FS1DB1NU03*%/V`B**12A^S1%SV]^<,Y-Z/=GJK99VY.[W+S)X+*T/=3MVT
M:>5E(B:'FT>)1K:/:(NQ>P9^:94T^:0@80$#"(D78MU^RI$YMPKC3*<*]2D&
M=RJ45)+.40$J0RI$`9SJ!0$`_P#2339PB/X;D';1%,.B)(_;19Q']@[LNH0R
M::YH%9N)BB4%T2UZ)04.0WCD4JA#%'8?PU\YGG8NM0V]YN-QZDYCF0S.LG,)
M!`>P6%JTN;W@.:X>D44V^D\<=UT\L8VFKF\T'P/.D-/8:K1*?>0BG2+L037.
MB<%&Z:H&%(BQ!'TE%"`("?T3@!R@.X&,``8!#<!O#I-U4@M9()PYDCV8@.KE
MS4J'4J*EIQH?=)&((J%7:WH)N8W1XM!P)'&G:!Z1@?S4*L]7\S.&<)./EGXN
M)JP"E&>LN)#BC'I&2=J*(HB7TB$%PW]("@78`'8`U-W;W6;E:!=WMW,)=4OB
M(JO(=2(4>2&GW0,S<E*4%<`%BV_V>V6]A@C92T@J^@J*N-6@$\>!K5;_`#&:
M(MK,G8$,U2B)"JQ<8]]F@DB!W2T0S>`L44B%V4++%+Z@C^'+Z:OC4NK^B:?J
MILH1!'ILVG11R<IC65>^!D@/N@8\ZF8]U>"Z.UVA=S6@G.=UTRY>]N8D^Z'N
M;3']BM/4JSVW)3AXQ_*G[@'GL#G28NN8G6;D`YA40]4#"*S8YQ$2@/(Q?&P@
M4-M1?WWU:#M/=IU[*)'0EPC?4%S14U;4_$PFI%:D8`&F"R/I&VF1S_,PC+GH
M7"E`>XT['?FXX55>IJ>,],*8'';D82[#]!V-QV$/J(@/[=QUKKZH[WDUJ=]K
M"ZK34&GZ%E#3-.$#<U$\KKPR>,<-T)-\D*2RL$S=E(8!*;T7:)'"!A`?("9)
M0!'7T+>4O2K[1_+UM>UU",QS.TV*4`\2R5HD8[PS,<#3B*XJ$/4.>&?>5^^`
MU8)W-];20?80I!NMSK6/*E8;O<9B.@*Q6(MU+S,O*O&\>P9M&I.0F6=NE$D$
MS*J"5,@"8!.H<I0W$0#4C%9:YXOC%NT5W=^07M=V_E7I9)C36Z-(QC#O2D(K
M'UQ=^V"LSZ+0Q2*H/&]>C`;JG(!0$[@>8<A#1%TBZ(DS_.=B%G?ND=AOI!1;
M3.&9Z-O";TPD!96&*B]BY*)3Y[\RO7,@V4$I0YCZ(;?CHB7_`/Y?[N;5V<9>
M.J]\M3&(?KRQ+?BQO+.D&#:15?'<%M<4S<NS)E7DUW*[,R#8IQ4.0A^!!`IM
MB+J8T1<C'^8OMD6EF'`4(UDV2TK&5*W.96.2636>QZ,DXK@QRKQLF8RS9-Z5
MLH*0G``4X&VWV'1$[?XA;=7[9T#P+^1R["47@*NTK\\DS<)+*14XP;-_>1KY
M-,QC-G:'J!R(<`,&_P!-$5'?G3Z3K9%QFCVHQM#>M><7L54,AM6*8>O.4!$#
M.QEEB?\`&6J@E7.`)AZJI7.P\N(`!%7CX/\`Y)H9%B7J/FRTQ\4#(?<XDLUB
MD"1Z"B1@%%S2EW[]5-L!T!21]@F(E54.JH&Y_'$B>MWCZH0'<OKW:,3/G3>,
MG%4PG:+854P42A[;'MUCPCER8A#.#Q*CLY/<IIF**J90\^`T1<L'1/M/D/XI
M^U5IP=VA@9>M4&VNV<9<4E&BZY8=9NX<H0]_KQT`51F()4CA07)VH+BL1$"$
M'F0P:(NSJF7:HY$K<7<*+9(2VU>:;D=1D[7Y)I+1;Q(Y0-NB\8K+H&.3?8Y>
M7(AO`@`Z(MF.<J93'.8I"$*)SG,(%*4I0$3&,8=@`I0#<1T1<YOR>?(C4\CW
MJ@=#.OMK":G\G9(HM/R;>*C)*&1A&\S:HQC_`"O"34:N5)1^[3.)'BB1S@FF
ML!0$IRF$")[EENM0P)AQ>WY!G6L)5L<4ENO-2LF[(011@(8A3I$57/S>2+P6
MO!),!,JNL8"E`QC`&B)$/Q`SW_=;VN[=]T[(Z:2#YW.DI5+8J''W<#&-D$&R
M$BU;G-ZC9O*UI5),W@""<3^.6^B+HVT1(@^?O$#.S]2X[,J0-FTIARVPKARZ
M,9,KI_$VE^C54XPA3_>X31?3GN.!`Y!Q$W[H#HBA3X!NY-6L6,Y[JW<K4R8W
M2J33R9QQ%R;I-F,Q59,J+Q['0_NC$&0DVTVN\7.@D)E"H??Q`H;Z(NDK1%3;
MM7UI7S(R9V6IJ(-KQ"-A;(HKG21;S3'U%%/9JJJ"1))P4ZPB50Y@````']&H
M&^<SRC.Z^6,.[-H.BAZA6$'+:UY#674(<YPB<XEH:\%Q+7N<!0`'``+,?2OJ
M4S9TS]-U4.=HDS\Q(J3&Z@&8`5)%!B`/%*+F<89@JS]>.DL>7))P@H9$YT(*
M3>,U!(IN<6SUJU.V<DY`.QR&$H_IVUIJN>CO7'I_JS[&]VWK;)XWEI++.XDB
M<1QY<L;#&\>+'$%2PM=S;0U:W;<6^H69C<*XRL:X?YFEP</00%E:Q64$2@!J
M)=OM\`'\M3(AMON`A_@AV\?7]>K^TL]5H699MOZ\"!0#Y&ZIX_Z=%2S3;:><
M+ZR_WH_M+]R[7*+D>2M&NPFXE+R&LS7T(4"%^C+^J0-@UW5YJ'5:Y&>70->+
MPT#_`*-UV#*.$78,%3QG;,>#+VR`^^C]/UE\!Q6<GN3B4*'>3"<P%*`5J9$3
MB)MB@4/9<A,8?I^.L9Z[H?6+6G<MFW]?XT;_`$-R2:X4IRJDE=M#J&V(!7YZ
MQP_G1_:5J>O?4*_W.?CI_(,8]J52CG"+U=G*(BWF)@Q#D6(Q38K`1PR*9385
M#J)[<"B4-C"&I(^6WR)=0=][IM=R]4+2;2-E6TK)I(YVEEU=%I#FPMB?1\0+
MJ&1TC*90Y@HX@C&6_P#J]H6C:?)8;?E9=:M(TM#F&L<=<"XN&#L,``>)!X`I
MS#-HV8-&S%FB1NT9MT6K5!/<$T6[=,J2*1`$1$")ID``_4&M[]A8VFEV,.FZ
M?&V*PMXFQQL;\+&,:&L:/!K0`/`*',TTEQ*Z>8ETSW%SB>))-23Z2EN=J/C)
MQUV\R!,W+*&;NP#6NRT7$QI<55BUU^(QRP/%,FS,7S>-"K+2KIU(&;^LN5T\
M<(BJ<1*0OV@%6N-5QIWP4=<<9RK>?Q5FSLKC&>0725&6J%SJ[19RFG_[9XU=
MTU['.T#^-P41,(;>!#1$YFJ0(U:L5ZM&EI.>&`AHV'&;FE&ZLQ+#'-$F@R,H
MJT;M&JD@\]+U%C)I)D%0P\2E#QHB65V'^)[&79Z\6:UY3S[V1?U^QR#V2+C%
MA;ZRPQ]#+/7`N!3CHQ&GA(+-V_(2)INW3DI2_@(@`Z(JZMO\O=TQCUTWD3=,
MZ0\B@/-I)Q5M@F,@R6#]U9JZ;U<BJ*I1^@@.B*[=;Z!-*QUVFNN[/LWV5<Q\
MM-(2J.17]GISG)$0W03=I?DL;,&I(1Y8M4KH.0*M%5MTR[*!YW(J7ROP`]2;
M(Y"2N&3.PMSG3ID([L%HNT'*R[XQ=]U%W"U6X$Y"(CP2*FD7?[2AHBVFD_!_
M@O%L@QDL2]A.TN,5VCKW2J%3O572CY`_-,X@]BY&ER$:IR]/83%2*H(".YOI
ML1.;D(J/EHMU#2K5"3C7[-1@_9ODDW#=ZU62%%=%RBH04E2+$$0,`AL._P!-
M$2+S_P"7KZ5?GDM.-K5FM@I(3#F78M&-HK[9"O\`N%/5(QA5DZL#Y!JU.(BD
M*BRBQ=_)Q\:(F#=2ND5;ZA+V8E4S)F[(<%8&T<V95G*=HBK+%5<&!G9C*0"Z
M$#'RY5'H.0*K[ERX#9(G$"^=R*0.R'3WKOVQK9JYG#&T);2IIG+'3)BK,)^)
M6$/X3AG+1ZS5V?VQPY$26,J@!M]R#N.Y$LVI_#?:,!S)W_4SNQGS$48Y4.JX
M@9=Q4[7$L_/\)"(CI&I.&#9L7SN!DC";\1'1%N%J^,?L;F1FK7,^?(IV`M5/
M<)D1<1E.98^I#]5/F852>_AZ(U.',IM@'Z_IW#QHBV[`7PL],<`WJL9*BXNY
M7>[5"99V&$G[S82OW;>;CUDG+*35+%LXE!PZ;NT2JE$Y#!S#R`AXT1;/V5^*
MK%O:S(%INV5LW]AG419'#-PVQM$V^OQN/ZX9JQ:,3$AXI&J^]63=>U]50'KE
MWLJ<PEXAL`$4-T/X..O6)Y5":Q/F_LKC:2(Y;KNEZK=*PV3DDD%"G]I(,W5.
M=LG""I2B0PBGZ@%'[3`(`($3G8MC^61D=&^Y<//R]BT8^\>&(=V[]HW30]RZ
M.F1-,SA?T^1Q*4H"81V``\:(E+9I^'K$W82UV"Q9<["]F[?&3<@O(-:2[N54
M;TZ!.JY,Z(C%Q;&EM3JHMC&V2]VHY,4-AWY``@10XP_R^O3F&=)R5?O>>:],
M-P.+&9A+A!QTI'K&()2.&CMO6"*$53$=P`=RC]#`("("17@+T.0+UG5ZT?\`
M<QV0&.5F6\H&3ALE._\`U%-F@+D1@2304D(P(E87'W[LQ<?PR[*AYW(K]:(O
M!TTU-O4(0^WTYE*;;]FX#MKT?''(*2-#@.\`_I7D.<WX20O'MF__`"$?^D3_
M`'=<?RUM_#9^Z/H7MS)/K'VE'MF__(1_Z1/]W3Y:V_AL_='T)S)/K'VE`-T`
M$!!!$!`=P$$R`("'T$!X_4->1;VX-1&RH_9'T)S)#^L?:LVN9>B-$6CY*M3V
MCT.U6Z.C&\R\KT0YE$8QU)M(9!Y[;B91-22?'3:MMDN1@$PAR$`*'D0T15_Z
M=YLOW87'DGE.X0L57H:;G'#6F1,>W>HN$8J,5<M'"T@H\>.A=+.52$,"B8$3
M-YXAMMHBMDX4.BW7533,LHDBJH1$O[RIR$,8J9?[QS!L'[=$4`]?\M7K*[&X
M.;SBRP8P6K]B5B8I">:/69YQB51V4KYH5ZBB9=%,$"[JDW34Y@)?&B*PFB(T
M1?/&7B@D@AADX\)<4/=!%^\;_F(MM]O<`R]3W/H;^.?'CO\`CHB^AHBH;D+L
MQDR,[543KC6*I`)-YL["PSDX\=&DY#^21='0>OFS)@_1&+6$$S<1<)G#QOMM
MHBOEHB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB6/\I.9C4+
M!C/&\.=9:SY@GF-:38,1$908!,YW4D[8I$`RRJGO&[=#8I1\K?T:(H?P[F/L
M7B/,O57`,_4*K6\<7ZGG9,JRV;.5;;#PT'$MQ&QVXP2!P83T@Z*EZB9T$`(=
M90HI\@\$5PN[79*W==L;NYFE5M*0FUF"[M*?G&CL]5B2(NFK,&BRB"K,)"?>
MJO"F:L4URKJI)JJ`4Q$C[$4F]?+Y<Y;KS2LB9E]G%6%[46UDGE"IBT(@T58I
MO2JN4%5#F;NC)#]Z8B`@;QL`^-$5$9GN1FG(.-<P]EL9?RU4,&XB3>?RBULL
M6^=S&5I"->>@^,LJ218A'1WH``D1*D5;FJ7[QXCHB8S0<I&ON$:IF"*@G#HU
MJH<5=65>17(FX5_,XQ*13CR.5"&(5393CR$!#]6B)&\'DGL!>YOM#WPIT[!T
MQIBR,6@F-6G4G5J;RM<8.':\A`1TI%R3&*37CS-$0.Y!(X*"<O'8`'1$Z[K5
MEI_FW!..\J3#!G&2EKK+*6DV<>*GL$7BK<JC@&8+*N%DVXF'[2G.<P!]1'1$
MH3#N1\IYP[C]A<A88@XB4FF2"-1J%YLY%W=2IE,%5^+L[Q!H[8*R,H[5X"U3
M2<I_^4?<IP^A%?[X_NP>1.P&,+-)Y*2BG,[5KK,5H)R$**<?)HL`;@!03%=R
M4SAN8PB<Y3`0P'```-AW(I3O^?7PW.1Q=B-E#V"UUY@:2O\`:IEP/\CXO8B)
MP0/:%6[ED+R15(@N<6";I!R4B.X_OAHBA;HEFO-O8,N3\B9$<P849O9#UBC-
M8&*>1C)=S$;C+R#<LB\?NUH]=-RAZ1A4,`F`WW#]`(H%[*=XL\XZ[(43&-'I
M44:/F)1FWCJ?(LWJMNN[)ZZ(U;2?J)NT"0L=+.R*M6H*-]T54%%#F.0Q2E(K
MI=<'';9:?R!_W'Q=%95]95@\H2U2<@HX`5_4_,&+IN,I(*MFK1$J7`%/O,J*
M@\A*(%*14<RCWQSVP[1TC$U`QZT<L9TJB<?1GS5VC;Y$SMV\B6\I9U%'"85U
MBW<-1<&160142:;+G.*2A#:(M+JO>?L_(Y(["4%-/'-A2H$([FE+PV82#*E4
M!M$QRK^74?E4G3JOS<$5&C5,'0&7?(FX\@,"8$5]>AN8<HYQP<2^912CC/'E
MEF6E<E8UDX8MYVO,U"(I28).%U^0&?E73*)1``(F`#N8!$2+=,@9^=%NC_%6
M)6D/8+I!QYI:]V.9<"%*Q;$E2.O[VUJH.&8NWWMR`J,>FZ;N@1.17]PP#HBA
M;HWF?-N?GN5K]D"0KZE$C+0_I5-:5Z*>1T;(.8%1HD\L469^^D'2T6^$%"DW
M54#GO]P[:(F%:(C1$:(C1$:(C1$:(C1$:(DI]A7-B:_(E#7'(^)\F7W&F-:`
MV<8>)3Z5.VB/EKW+,8,S]DY5C6+QLQ1174<F.NJ`II'3#EHBN/U]PC>)?*-L
M[19W9-6.0[8S"'H='15([1QC1/616:1KAV0YB.[$_;M&QGBA02`JI3AP+OL!
M%4KY`#Y>RSV'PKA.N8EN5TQK6WJ5WGBM&3YK5K/9/;`G"I2-G!HI%PS&$1>K
MBN9<QBG/L3<IC%T17Q[%4;)M^ZC9$HD6>,;94G<:!'`-<1591);$1-FL^2A6
MRSETN@S4,@H1!,RJA@*(%Y".B)6Y*=D7-O7;KQTRQ=CF]TUJE$5"P=A+W;ZI
M,UR$K3UC%()SD`@M(M6;:<>R<@X5$4TE/4$$-_P'1$Q'MY?X?JATZLYZNH>,
M4A:LRQ[CU+D45/SIVP59P;7D`$`QS(M#_0`W$/&B)<-`J%^M?36@].\38]O<
M-=<EJ*RF;K7<J?.5^L4IE)%;GLJ2TG(-VB$Q(/W!R"V3(L43%2.(`;\")G^3
MJ[+=>>G<Y2L,5^S66>I.-C5:AQ%=C',U//)-)D+9DI[:/;G6.(J;F.<";!XW
M^NB*BN%WMZZH8H@.MM'P-D*:S7DC'B5SD;^TB7O\HQ^1;4#QD2'L,R,8JVC4
M(,[(JBYUG!2H%5`3<>6^B*\N)\./>I7522J-#9?S/>("LSUG<@U;*J'M%^=,
M/7<JHM4S&7'WCINF0A"F$?M\#YT1)7DK3VI9=*9^I43!.582P76]/39FNLE#
M2:ELNKRS@1DNV@XG\K;R)H46K<2+K%]8A`,'$Q!$1$B=?TBIMKH.`ZI5K#64
M*?&Q:!4JS!N$%TK,$2=!NL+^WF54*7\]=/%%0.0$$!(F0FY?.B*L'7/$-RRE
MW0SCV@RQ1K'7(FK.V=*P@SML0\B'OY<@U.K*2J3.2125<-/6>@9LX3*5/U.7
M$1$HZ(FB6*6-`0$U.$CI"8/#Q3^3+%1+95Y*21F+55R#&.:($46<O70I\$DR
M%,8YS```(CHB1[CVBYMH6*.Q/<NSXJR#8^SN79*7@,=TUI5Y9U:*?`ODBUV)
MFPKZ;-:3C'39)R95<%"`7T4"FV*`[Z(HYS!@')6#NI^*L,5B@7JW7OL;>D+!
MV!L-2B7K^49I'>,),\0==LQ>"P0.W_AG36Y\%C*"/@>($3>Z''9#QEU7=M4Z
MO$1MSJ.,K$XJ5-K+5P;T'\7!/W4!%K`=P\,]F9%\DF=<4P(`KKB4"`(;:(D>
M&L_:5KTKMU5I&"LFUVW7NY2+K,UY>0$RYM=E>6&71:J1E<A?8)2;EBG#';H+
M."^LD9`ITR`0X"8")U/1VEVW'_7ZH5:R51M26$<S;C6JXJ50UD:,';=-])KV
MUR<Y2+R[^PN7BY"@@@9!JHDB<ICD,<Q%;_1$:(C1$:(C1$:(C1$:(C1%C-Z7
M,G/T_4\^GRX\_P!?#?[O]&B+)HB\?P_4_J>KQ';]WU.&X;_WN._]&B+WHBQ)
M^CN?TO2WY?Q/3X;\O[_'^M^W1$L/Y(*7CZTGP*]S+FEGBW$L)D5DYG(-W0+E
M;0O$Z95$8.-+,5=-TTK1TRD7`%7B!TS<Q$!#B.B)G+?VW'_#BB(<2<A2X;B'
M'[!-P_5]-]$7Z-$7@?2]0-_3]7B.V_'U./X[?UN.B+WHBPC[?TPW]'TMPVWX
M>GRW\;?U=]]$6;1$:(C1$:(O!_3W)SX<N7\/GQWY?W-_/+]FB+V.VP[_`$_'
C?Z;?COHBQ?P.'_!]/D']CASW\?W>7+^G?1%ET1&B(T1?_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
